Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 2.173
Filtrar
1.
BMC Health Serv Res ; 20(1): 913, 2020 Oct 02.
Artigo em Inglês | MEDLINE | ID: mdl-33008384

RESUMO

BACKGROUND: Novel Coronavirus is a global pandemic affecting all walks of life and it significantly changed the health system practices. Pharmacists are at the front line and have long been involved in combating this public health emergency. Therefore, the study was aimed to explore pharmacy preparedness and response to prevent and control coronavirus disease 2019 (COVID-19). METHODS: A qualitative study was conducted in six pharmacies in Aksum, Ethiopia in May, 2020. We conducted six in-depth interviews with purposively selected key informants. Direct observation measures were made to assess the activities made in the medicine retail outlets for the prevention and control of the pandemic. Interview data were audio-recorded, translated and transcribed verbatim. Thematic analysis was employed to analyze the data and OpenCode version 4.02 software was used to facilitate the data analysis. RESULTS: The thematic analysis has resulted in seven major themes. Good preparedness measures were undertaken to control and prevent COVID-19. Study informants had good knowledge about the pandemic disease and reported they had used different resource materials to update themselves. Preparing of alcohol-based hand-rub, availing finished sanitizers and alcohol, and advising clients to maintain physical distancing were the major counseling information being delivered to prevent the disease. Some tendencies of irrational drug use and false claims of COVID-19 were observed at the beginning of the pandemic. Interview informants had reported they were working with relevant stakeholders and appropriate patient education and support were given to combat the pandemic. CONCLUSION: The study revealed necessary pharmacy services has been rendered to all clients. However, availability of drugs and medical supplies were scarce which negatively affected the optimal delivery of pharmacy services. The government and other responsible bodies should work together to solve such problems and contain the pandemic.


Assuntos
Infecções por Coronavirus/prevenção & controle , Pandemias/prevenção & controle , Assistência Farmacêutica/organização & administração , Farmacêuticos/psicologia , Pneumonia Viral/prevenção & controle , Adulto , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/epidemiologia , Etiópia/epidemiologia , Feminino , Pesquisa sobre Serviços de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Preparações Farmacêuticas/provisão & distribução , Farmacêuticos/estatística & dados numéricos , Pesquisa Qualitativa
2.
Farm. hosp ; 44(4): 135-140, jul.-ago. 2020. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-191014

RESUMO

OBJETIVO: Analizar la situación de la implantación y desarrollo de la telefarmacia aplicada a la atención farmacéutica a pacientes externos de los servicios de farmacia hospitalaria en España durante la pandemia por la COVID-19. MÉTODO: Se envió una encuesta online de 10 preguntas a todos los socios de la Sociedad Española de Farmacia Hospitalaria a las seis semanas del inicio del periodo de confinamiento por la pandemia. Se solicitó una única respuesta por hospital. Se incluyeron preguntas sobre la realización de atención farmacéutica no presencial con dispensación a distancia previa al inicio de la crisis sanitaria, los criterios de selección de pacientes, los procedimientos de envío de medicación y los medios utilizados, el número de pacientes que se han beneficiado de la telefarmacia y el número de envíos realizados. Por último, se identificó la realización o no de teleconsulta previa al envío de medicación y si la actividad quedó registrada. RESULTADOS: Un 39,3% (n = 185) del total de hospitales públicos del Sistema Nacional de Salud pertenecientes a todas las comunidades autónomas respondieron a la encuesta. El 83,2% (n = 154) de los ser-vicios de farmacia hospitalarios no realizaban actividades de atención farmacéutica no presencial con telefarmacia que incluyeran envío de medicación antes del inicio de la crisis sanitaria. En el periodo de estudio se atendieron 119.972 pacientes y se realizaron 134.142 envíos de medicación. La mayoría de los hospitales no utilizaron criterios de selección de pacientes. El 30,2% de los centros seleccionaron en función de las circunstancias personales del paciente. La dispensación domiciliaria y entrega informada (87%; 116.129 envíos) fue la opción utilizada de forma mayoritaria para el envío. Los medios para hacer llegar la medicación fueron, principalmente, la mensajería externa (47%; 87 centros) o medios propios del hospital (38,4%; 71 centros). Un 87,6% de los hospitales realizaron teleconsulta previa al envío de medicación y el 59,6% registró la actividad de telefarmacia en la agenda de citación. CONCLUSIONES: La implantación de la telefarmacia aplicada a la atención a pacientes externos en España durante la pandemia ha sido elevada. Así se ha podido garantizar la continuidad de los tratamientos de un elevado número de pacientes


OBJECTIVE: To analyze the status of the implementation and development of telepharmacy as applied to the pharmaceutical care of outpatients treated at hospital pharmacy services in Spain during the COVID-19 pandemic. METHOD: Six weeks after the beginning of the confinement period, an online 10-question survey was sent to all members of the Spanish Society of Hospital Pharmacists. A single response per hospital was requested. The survey included questions on the provision of remote pharmaceutical care prior to the onset of the health crisis, patient selection criteria, procedures for home delivery of medications and the means used to deliver them, the number of patients who benefited from telepharmacy, and the number of referrals made. Finally, respondents were asked whether a tele-consultation was carried out before sending patients their medication and whether these deliveries were recorded. RESULTS: A total of 39.3% (n = 185) of all the hospitals in the National Health System (covering all of Spain's autonomous regions) responded to the survey. Before the beginning of the crisis, 83.2% (n = 154) of hospital pharmacy services did not carry out remote pharmaceutical care activities that included telepharmacy with remote delivery of medication. During the study period, 119,972 patients were treated, with 134,142 deliveries of medication being completed. Most hospitals did not use patient selection criteria. A total of 30.2% of hospitals selected patients based on their personal circumstances. Home delivery and informed delivery (87%; 116,129 deliveries) was the option used in most cases. The means used to deliver the medication mainly included the use of external courier services (47.0%; 87 hospitals) or the hospital's own transport services (38.4%; 71 hospitals). As many as 87.6% of hospitals carried out teleconsultations prior to sending out medications and 59.6% recorded their telepharmacy activities in the hospital pharmacy appointments record. CONCLUSIONS: The rate of implementation of telepharmacy in outpatient care in Spain during the study period in the pandemic was high. This made it possible to guarantee the continuity of care for a large number of patients


Assuntos
Humanos , Assistência Farmacêutica/organização & administração , Serviço de Farmácia Hospitalar/métodos , Pandemias , Infecções por Coronavirus/epidemiologia , Pneumonia Viral/epidemiologia , Serviços Terceirizados/métodos , Serviço de Farmácia Hospitalar/organização & administração , Espanha , Inquéritos e Questionários , Telemedicina/tendências , Infecções por Coronavirus/prevenção & controle , Pneumonia Viral/prevenção & controle
4.
Aust J Gen Pract ; 49(8): 530-532, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32738870

RESUMO

BACKGROUND: During the COVID-19 pandemic, vulnerable and older people with chronic and complex conditions have self-isolated in their homes, potentially limiting opportunities for consultations to have medications prescribed and dispensed. OBJECTIVE: The aim of this article is to describe initiatives to ensure ongoing access to medications during the COVID-19 pandemic. DISCUSSION: Cooperation between wholesalers and purchase limits in pharmacies have helped to ensure supply of essential medications. Therapeutic substitution by pharmacists is permitted for specific products authorised by the Therapeutic Goods Administration. Prescribers are permitted to issue digital image prescriptions, and implementation of electronic prescribing has been fast-tracked. Expanded continued dispensing arrangements introduced during the bushfire crises have been temporarily extended. Pharmacists are permitted to provide medication management reviews via telehealth. A Home Medicines Service has been introduced to facilitate delivery of medications to people who are vulnerable or elderly. Anticipatory prescribing and medication imprest systems are valuable for access to end-of-life medications within residential aged care.


Assuntos
Infecções por Coronavirus , Medicamentos Essenciais/provisão & distribução , Acesso aos Serviços de Saúde/organização & administração , Conduta do Tratamento Medicamentoso , Pandemias , Assistência Farmacêutica , Pneumonia Viral , Idoso , Austrália/epidemiologia , Betacoronavirus , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/prevenção & controle , Prescrição Eletrônica , Humanos , Conduta do Tratamento Medicamentoso/organização & administração , Conduta do Tratamento Medicamentoso/tendências , Múltiplas Afecções Crônicas/terapia , Pandemias/prevenção & controle , Assistência Farmacêutica/organização & administração , Assistência Farmacêutica/tendências , Pneumonia Viral/epidemiologia , Pneumonia Viral/prevenção & controle , Telemedicina/métodos , Telemedicina/organização & administração , Telemedicina/tendências
5.
Am J Pharm Educ ; 84(6): ajpe8157, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32665728

RESUMO

The administrative response to the coronavirus identified in 2019 (COVID-19) pandemic for a variety of units housed in the University of Oklahoma College of Pharmacy is described. Continuity of operations, essential vs nonessential personnel, distance learning, online testing procedures for the Doctor of Pharmacy degree program, and the impact on development are discussed.


Assuntos
Infecções por Coronavirus/epidemiologia , Educação em Farmácia/organização & administração , Assistência Farmacêutica/organização & administração , Pneumonia Viral/epidemiologia , Faculdades de Farmácia/organização & administração , Betacoronavirus , Educação a Distância/organização & administração , Docentes de Farmácia/organização & administração , Humanos , Pandemias , Assistência Farmacêutica/economia , Faculdades de Farmácia/economia
6.
Afr J Prim Health Care Fam Med ; 12(1): e1-e4, 2020 Jun 04.
Artigo em Inglês | MEDLINE | ID: covidwho-531615

RESUMO

The public sector primary care facilities in Cape Town serve a large number of patients with chronic diseases such as human immunodeficiency virus, tuberculosis, diabetes, hypertension, asthma and chronic obstructive pulmonary disease. Prior to the Coronavirus disease 2019 (COVID-19) epidemic, stable patients with chronic conditions attended the facility or support groups to obtain their medication. During the COVID-19 epidemic, these patients would be put at risk if they had to travel and gather in groups to receive medication. The Metropolitan Health Services, therefore, decided to offer home delivery of medication. A system of home delivery was rapidly established by linking the existing chronic dispensing unit system with the emerging approach to community-orientated primary care in the Metro. Medication was delivered as usual to primary care pharmacies, but then a variety of means were used to disseminate the parcels to local non-profit organisations, where they could be delivered by a city-wide network of community health workers (CHWs). Innovations included various ways of delivering the parcels, including via Uber, bicycles and electric scooters, as well as Google forms to monitor the success of the initiative. It was estimated that up to 200 000 parcels per month could be delivered in this way via 2500 CHWs. The new system was established throughout the Metropole, and its strengths, weaknesses, opportunities and threats are further discussed. The initiative may prevent COVID-19 amongst people with comorbidities who would be at risk of more severe diseases. It may also have de-congested primary care facilities ahead of the expected surge in COVID-19 cases.


Assuntos
Doença Crônica/tratamento farmacológico , Infecções por Coronavirus/epidemiologia , Assistência Farmacêutica/organização & administração , Pneumonia Viral/epidemiologia , Agentes Comunitários de Saúde , Humanos , Adesão à Medicação , Pandemias , Atenção Primária à Saúde , África do Sul/epidemiologia
7.
Afr J Prim Health Care Fam Med ; 12(1): e1-e4, 2020 Jun 04.
Artigo em Inglês | MEDLINE | ID: mdl-32501022

RESUMO

The public sector primary care facilities in Cape Town serve a large number of patients with chronic diseases such as human immunodeficiency virus, tuberculosis, diabetes, hypertension, asthma and chronic obstructive pulmonary disease. Prior to the Coronavirus disease 2019 (COVID-19) epidemic, stable patients with chronic conditions attended the facility or support groups to obtain their medication. During the COVID-19 epidemic, these patients would be put at risk if they had to travel and gather in groups to receive medication. The Metropolitan Health Services, therefore, decided to offer home delivery of medication. A system of home delivery was rapidly established by linking the existing chronic dispensing unit system with the emerging approach to community-orientated primary care in the Metro. Medication was delivered as usual to primary care pharmacies, but then a variety of means were used to disseminate the parcels to local non-profit organisations, where they could be delivered by a city-wide network of community health workers (CHWs). Innovations included various ways of delivering the parcels, including via Uber, bicycles and electric scooters, as well as Google forms to monitor the success of the initiative. It was estimated that up to 200 000 parcels per month could be delivered in this way via 2500 CHWs. The new system was established throughout the Metropole, and its strengths, weaknesses, opportunities and threats are further discussed. The initiative may prevent COVID-19 amongst people with comorbidities who would be at risk of more severe diseases. It may also have de-congested primary care facilities ahead of the expected surge in COVID-19 cases.


Assuntos
Doença Crônica/tratamento farmacológico , Infecções por Coronavirus/epidemiologia , Assistência Farmacêutica/organização & administração , Pneumonia Viral/epidemiologia , Agentes Comunitários de Saúde , Humanos , Adesão à Medicação , Pandemias , Atenção Primária à Saúde , África do Sul/epidemiologia
8.
J Oncol Pharm Pract ; 26(6): 1429-1440, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-32580641

RESUMO

PURPOSE: During COVID-19 pandemic, cancer patients are considered one of the most vulnerable to infection since they tend to have advanced age, multiple comorbidities, and are often immunosuppressed by their cancer or therapy. Hence, the Saudi Oncology Pharmacy Assembly has issued recommendations to reduce the frequency of cancer patients' visits to oncology centers during the pandemic while maintaining the access to cancer therapy and minimize the risk of exposure to coronavirus disease. MATERIALS AND METHODS: A qualitative methodological approach was conducted in April 2020 using a virtual panel discussion for collection of recommendations. RESULTS: A total of 12 expert oncology pharmacy practitioners shared their knowledge and experiences in managing oncology patients during the COVID-19 pandemic. The participants recognized many fundamental recommendations that were already applied in many cancer centers since the start of the COVID-19 outbreak. On that basis, the panelists developed eight practice-related recommendations for action, with a main focus on cancer treatment modification. CONCLUSIONS: In conclusion, delivering cancer care during the COVID-19 pandemic carries significant challenges. This paper addressed suggestions to properly manage cancer patients during difficult times. Implementing changes in practice mandates a national collaborative effort from different sectors to guarantee the quality and continuity of care. The SOPA expert panel developed these recommendations, to ultimately contribute in maintaining access to cancer therapy while minimizing the risk of COVID-19 exposure.


Assuntos
Infecções por Coronavirus/epidemiologia , Neoplasias/terapia , Pneumonia Viral/epidemiologia , Humanos , Oncologia/normas , Neoplasias/epidemiologia , Pandemias , Assistência Farmacêutica/organização & administração , Arábia Saudita/epidemiologia
9.
Ann Hematol ; 99(7): 1615-1625, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32483668

RESUMO

Ibrutinib treatment has been shown to increase survival in patients with B cell malignancies. Real-life data suggest a large part of discontinuations are due to toxicities, impairing ibrutinib efficacy. We aimed to assess the impact of a pharmaceutical care program on the efficacy and safety of ibrutinib. This single-center, cohort, observational study enrolled patients with B cell malignancies. Patients were either assigned to the program or to receive usual care, based on physician decision. The program was conducted by clinical pharmacists specializing in oncology and included patient education for management of toxicities, adherence monitoring, interventions to reduce drug-drug interactions, and follow-up of transition from hospital to community. Between February 2014 and May 2017, we enrolled 155 patients, including 42 (27%) who were allocated to the program group and 113 (73%) to the usual care group. The effect of the program was beneficial in terms of time to treatment failure (p = 0.0005). The 30-month progression-free and overall survivals were significantly superior in the program group (respectively p = 0.002 and p = 0.004). Grade 3 or higher adverse events occurred more frequently for patients in the usual care group (15%) than program group (8%). A pharmaceutical care program provides a personalized environment for outpatient monitoring and control of the key risks associated with oral anticancer agents. This study shows evidence that management of ibrutinib treatment by clinical pharmacists results in significant improvement in survival and better tolerance than usual care.


Assuntos
Neoplasias/tratamento farmacológico , Neoplasias/mortalidade , Assistência Farmacêutica/normas , Pirazóis/uso terapêutico , Pirimidinas/uso terapêutico , Melhoria de Qualidade , Tempo para o Tratamento/normas , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Eficiência Organizacional , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Assistência Farmacêutica/organização & administração , Assistência Farmacêutica/tendências , Farmacêuticos/organização & administração , Farmacêuticos/normas , Análise de Sobrevida , Fatores de Tempo , Tempo para o Tratamento/organização & administração , Tempo para o Tratamento/tendências , Falha de Tratamento
10.
J Oncol Pharm Pract ; 26(5): 1225-1229, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32408842

RESUMO

Response, action, and adaptation of the way health services are delivered will impact our ability to provide optimized and continuity of care while acting within resource constraints imposed by COVID-19. Care for patients with cancer is particularly important given increased infection rates and worse outcomes from COVID-19 in this patient population, as well as potential adverse outcomes if treatment pathways need to be compromised. In this commentary, we provide a global oncology pharmacy perspective (including both developed and developing nations) on how COVID-19 has impacted access to and delivery of cancer therapies. This perspective was prepared by the International Society of Oncology Pharmacy Practitioners, with input from national and regional oncology pharmacy practice groups (42 practice leaders from 28 countries and regions) who contributed to a snapshot survey between 10 and 22 April 2020. Specifically, we highlight challenges related to safe handling of hazardous drugs and maintaining high-quality medication safety standards that have impacted various stakeholders.


Assuntos
Antineoplásicos/provisão & distribução , Gestão de Mudança , Infecções por Coronavirus , Oncologia , Neoplasias , Pandemias , Assistência Farmacêutica , Pneumonia Viral , Betacoronavirus/isolamento & purificação , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/prevenção & controle , Saúde Global , Humanos , Oncologia/métodos , Oncologia/tendências , Neoplasias/tratamento farmacológico , Neoplasias/epidemiologia , Pandemias/prevenção & controle , Assistência Farmacêutica/organização & administração , Assistência Farmacêutica/tendências , Farmácias/estatística & dados numéricos , Pneumonia Viral/epidemiologia , Pneumonia Viral/prevenção & controle , Inquéritos e Questionários
12.
Zhongguo Zhong Yao Za Zhi ; 45(6): 1259-1262, 2020 Mar.
Artigo em Chinês | MEDLINE | ID: covidwho-54733

RESUMO

The outbreak of coronavirus disease 2019(COVID-19) seriously endangers people's health. Traditional Chinese medicine(TCM) has been recommended for the treatment of COVID-19 in Novel Coronavirus Pneumonia Prevention and Control Strategy, which have made outstanding contributions to the prevention and control of the epidemic. The wide application of Chinese medicine asked the pharmacists and doctors, nurses, and medical technicians in Wuhan and around the country to stand on the front line of COVID-19 treatment, and provide pharmaceutical care services, which has effectively guaranteed the safety and rational use of Chinese medicine. This article will introduce the TCM cognition of the COVID-19, analyze the clinical application of Chinese medicine and the entry point of pharmaceutical care, and clarify that clinical Chinese pharmacists can participate in making medication therapy plan, medication reconciliation, and prescription review, promoting rational drug use, pharmaceutical monitoring, and drug risk management. The participation of clinical Chinese pharmacists in the prevention and treatment of COVID-19 is conducive to improving the level of rational use of TCM, by ensuring the effectiveness, and safety.


Assuntos
Infecções por Coronavirus/tratamento farmacológico , Medicina Tradicional Chinesa , Assistência Farmacêutica/organização & administração , Pneumonia Viral/tratamento farmacológico , Betacoronavirus , China , Humanos , Pandemias
13.
Zhongguo Zhong Yao Za Zhi ; 45(6): 1259-1262, 2020 Mar.
Artigo em Chinês | MEDLINE | ID: mdl-32281334

RESUMO

The outbreak of coronavirus disease 2019(COVID-19) seriously endangers people's health. Traditional Chinese medicine(TCM) has been recommended for the treatment of COVID-19 in Novel Coronavirus Pneumonia Prevention and Control Strategy, which have made outstanding contributions to the prevention and control of the epidemic. The wide application of Chinese medicine asked the pharmacists and doctors, nurses, and medical technicians in Wuhan and around the country to stand on the front line of COVID-19 treatment, and provide pharmaceutical care services, which has effectively guaranteed the safety and rational use of Chinese medicine. This article will introduce the TCM cognition of the COVID-19, analyze the clinical application of Chinese medicine and the entry point of pharmaceutical care, and clarify that clinical Chinese pharmacists can participate in making medication therapy plan, medication reconciliation, and prescription review, promoting rational drug use, pharmaceutical monitoring, and drug risk management. The participation of clinical Chinese pharmacists in the prevention and treatment of COVID-19 is conducive to improving the level of rational use of TCM, by ensuring the effectiveness, and safety.


Assuntos
Infecções por Coronavirus/tratamento farmacológico , Medicina Tradicional Chinesa , Assistência Farmacêutica/organização & administração , Pneumonia Viral/tratamento farmacológico , Betacoronavirus , China , Humanos , Pandemias
14.
J Oncol Pharm Pract ; 26(3_suppl): 33-39, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-32268830

RESUMO

The International Society of Oncology Pharmacy Practitioners organized a workshop to create learning opportunities on biosimilars in pharmacy practice on 10 October 2019. The topics that were covered included (i) the development and testing of biosimilars, (ii) the challenges of bringing biosimilars to market, and (iii) real-world data on patient safety and perceptions during biosimilar implementation. The development of biosimilars can take up to eight years and the extensiveness of the process depends on several factors, such as the complexity of the production process and regulatory requirements. Compared to generic products of small-molecule drugs, there is a higher barrier to market entry for biosimilars, explaining the small number of biosimilars in the market. Appraisal of biosimilars for inclusion in hospital formularies is also different from the review process of originator biologics, where the former is usually institution-led and has fewer restrictions on use. When several biosimilar products are available, factors that should be considered besides cost are licensed indications, supply chain confidence, clinical data, and product attributes. Real-world data have shown that biosimilars are well-tolerated and have safety data that are comparable to that of the originator product. Oncology pharmacists from the United Kingdom, Kenya, and Canada also presented their respective experiences with biosimilar use. Different countries at varying stages of biosimilar implementation faced distinct challenges. Nevertheless, resources to assist biosimilar implementation can potentially be shared between different regions. International Society of Oncology Pharmacy Practitioners is well-positioned to foster professional cooperation at an international level to drive biosimilar implementation.


Assuntos
Medicamentos Biossimilares/administração & dosagem , Assistência Farmacêutica/organização & administração , Farmacêuticos/organização & administração , Humanos , Neoplasias/tratamento farmacológico
15.
J Oncol Pharm Pract ; 26(3_suppl): 11-21, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-32268832

RESUMO

Background: The International Society of Oncology Pharmacy Practitioners (ISOPP) Biosimilar Task Force was charged to develop educational resources to address the learning needs related to biosimilars use of oncology pharmacy practitioners. To facilitate the process, the task force conducted a survey in order to identify unmet education needs as well as barriers for obtaining biosimilar education among oncology pharmacy practitioners. Methods: A cross sectional survey was conducted between 10 December 2018 and 18 February 2019. Members of International Society of Oncology Pharmacy Practitioners and national oncology pharmacy groups were invited to complete the survey. The survey contained 22 items and consisted of four sections. Descriptive statistics were utilized to analyze the survey results. Results: A total of 363 International Society of Oncology Pharmacy Practitioners members were surveyed, with 75 members providing a response (response rate = 21%). In addition, 11 non-International Society of Oncology Pharmacy Practitioners members also participated in the survey, bringing the total to 86 respondents. The top three areas in which respondents reported learning needs included evaluating comparative efficacy of a biosimilar to an originator's product (74.4%), managing the switchover to a biosimilar from the original product (74.4%), and understanding medication safety issues in relation to biosimilars use (73.3%). The most common challenges faced in obtaining education on biosimilars included limited financial support for education on biosimilar products (38.4%), heavy workload (31.4%), and inadequate educational resources (27.9%). Conclusion: This survey has identified numerous biosimilar learning needs as well as challenges faced in obtaining biosimilars education among oncology pharmacy practitioners. Educational activities should be created to address these learning needs, and innovative strategies should be considered to overcome practitioner's barriers in obtaining biosimilars education.


Assuntos
Medicamentos Biossimilares/uso terapêutico , Educação em Farmácia/métodos , Assistência Farmacêutica/organização & administração , Estudos Transversais , Humanos , Neoplasias/tratamento farmacológico , Inquéritos e Questionários
16.
J Oncol Pharm Pract ; 26(3_suppl): 3-10, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-32268831

RESUMO

With the development of innovative cancer treatments over recent decades, the cost of cancer care has risen exponentially, limiting patient access to patented originator biotherapeutics in many countries. The introduction of biosimilars to the market has created new opportunities as well the need for changes in practice within healthcare institutions. A 'biosimilar' is a biotherapeutic product which is highly similar in terms of quality, safety and efficacy to an already licensed originator product. Although biosimilars lack clinically meaningful differences in therapeutic activity as compared to the originator product, these complex biological molecules are not considered identical chemical copies, unlike generics, and minor differences in molecular structure and inactive compounds may exist. A thorough understanding of these differences and their clinical implications is necessary for optimising medicines-use practices involving biosimilars. This position statement, developed by the International Society of Oncology Pharmacy Practitioners Biosimilars Taskforce, aims to provide the global oncology pharmacy community with guidance to support decisions around biosimilar use. The 11 statements cover the regulation and evaluation of biosimilars, practical issues around local implementation, the education of healthcare staff and patients, and the requirement for ongoing pharmacovigilance and outcome monitoring.


Assuntos
Antineoplásicos/administração & dosagem , Medicamentos Biossimilares/uso terapêutico , Neoplasias/tratamento farmacológico , Humanos , Assistência Farmacêutica/organização & administração , Farmacovigilância
18.
Ars pharm ; 61(1): 9-13, ene.-mar. 2020. ilus
Artigo em Espanhol | IBECS | ID: ibc-188569

RESUMO

El presente artículo es fruto de la conferencia dictada por la Dra. Carmen Peña en el acto de apertura del curso académico de la Cátedra María José Faus Dáder de Atención Farmacéutica, de la Universidad de Granada. En él se narra de manera secuencial el nacimiento y desarrollo de la Atención Farmacéutica en la que resulto esencial el papel que la Federación internacional de Farmacéuticos (FIP) ha jugado para su desarrollo. Conjuntamente con la OMS publican en 1999 el documento "Buenas Prácticas en Farmacia: Estándares para la calidad de los servicios farmacéuticos" que se ha seguido actualizando hasta su versión del 2011.En España, mientras el proceso de la Atención Farmacéutica (Pharmaceutical Care) a nivel mundial, tomaba velocidad de crucero, un grupo de líderes de la farmacia española se movilizó para introducirlos conceptos de la Declaración de Tokio 93, en relación con los principios de la Atención Farmacéutica. En el momento actual estos pioneros, entre los que se encuentran entre otros, el Consejo General de Farmacéuticos y la Cátedra de Atención Farmacéutica de la Universidad de Granada responsable de la integración del grupo de Atención Farmacéutica de dicha universidad, presentan una apuesta decidida por la farmacia profesional a través de una oferta de servicios farmacéuticos de calidad dirigidos al paciente


This article is based on the lecture given by Dr Carmen Peña at the start of the academic year of the María José Faus Dáder Chair of Pharmaceutical Care, of the University of Granada. It narrates the genesis and development of Pharmaceutical Care and the essential role played by the International Federation of Pharmacists (FIP) in its development. In 1999, FIP and WHO together published the document "Good Practices in Pharmacy: Standards for the Quality of Pharmaceutical Services" which has been updated continually until its 2011 version. In Spain, while the global development of Pharmaceutical Care was taking off, a group of Spanish pharmacy leaders mobilized to introduce the concepts of the Tokyo Declaration 93, in relation to the principles of Pharmaceutical Care. At the present time these pioneers, among whom are the General Council of Pharmacists and the Chair of Pharmaceutical Care of the University of Granada which is responsible for the integration of the Pharmaceutical Care group of said university, are firmly committed to Professional Pharmacy by way of offering quality pharmaceutical services aimed at the patient


Assuntos
Humanos , Assistência Farmacêutica/tendências , Farmácias/normas , Qualidade da Assistência à Saúde/organização & administração , Assistência Farmacêutica/organização & administração , Assistência Farmacêutica/normas , Qualidade da Assistência à Saúde/normas
19.
BMC Health Serv Res ; 20(1): 113, 2020 Feb 12.
Artigo em Inglês | MEDLINE | ID: mdl-32050957

RESUMO

BACKGROUND: Pharmacists play a key role in ensuring the safe use of injectable antineoplastics, which are considered as high-alert medications. Pharmaceutical analysis of injectable antineoplastic prescriptions aims to detect and prevent drug related problems by proposing pharmacist interventions (PI). The impact of this activity for patients, healthcare facilities and other health professionals is not completely known. This study aimed at describing the clinical, economic, and organizational impacts of PIs performed by pharmacists in a chemotherapy preparation unit. METHODS: A prospective 10-week study was conducted on PIs involving injectable antineoplastic prescriptions. Each PI was assessed by one of the four multidisciplinary expert committees using a multidimensional tool with three independent dimensions: clinical, economic and organizational. An ancillary quantitative evaluation of drug cost savings was conducted. RESULTS: Overall, 185 patients were included (mean age: 63.5 ± 13.7 years; 54.1% were male) and 237 PIs concerning 10.1% prescriptions were recorded. Twenty one PIs (8.9%) had major clinical impact (ie: prevented hospitalization or permanent disability), 49 PIs (20.7%) had moderate clinical impact (ie: prevented harm that would have required further monitoring/treatment), 62 PIs (26.2%) had minor clinical impact, 95 PIs (40.0%) had no clinical impact, and 9 PIs (3.8%) had a negative clinical impact. For one PI (0.4%) the clinical impact was not determined due to insufficient information. Regarding organizational impact, 67.5% PIs had a positive impact on patient management from the healthcare providers' perspective. A positive economic impact was observed for 105 PIs (44.3%), leading to a saving in direct drug costs of 15,096 €; 38 PIs (16.0%) had a negative economic impact, increasing the direct drug cost by 11,878 €. Overall cost saving was 3218€. CONCLUSIONS: PIs are associated with positive clinical, economic and organizational impacts. This study confirms the benefit of pharmacist analysis of injectable antineoplastic prescriptions for patient safety with an overall benefit to the healthcare system.


Assuntos
Assistência Farmacêutica/economia , Assistência Farmacêutica/organização & administração , Idoso , Antineoplásicos/administração & dosagem , Prescrições de Medicamentos , Feminino , Pesquisa sobre Serviços de Saúde , Humanos , Injeções , Masculino , Pessoa de Meia-Idade , Segurança do Paciente , Estudos Prospectivos
20.
BMC Health Serv Res ; 20(1): 37, 2020 Jan 14.
Artigo em Inglês | MEDLINE | ID: mdl-31937299

RESUMO

BACKGROUND: Pharmaceutical care services have been recognized as the most highly regarded professional pharmacy practice model that allows the identification, intervention, and resolution of drug related problems. This practice provides significant clinical outcomes and can reduce direct and indirect costs for health systems. However, its implementation can be complex and challenging, needing study experiences that aims at overcoming obstacles, especially in free and universal healthcare systems. The objective of this study is to evaluate the implementation of Ambulatory Care Pharmacy services for older adults at Paulista Institute of Geriatrics and Gerontology (IPGG), which is recognized in the city of São Paulo for offering pharmaceutical care services for over 10 years continuously. This initiative and process is independent of external academic interventions or educational institutions. It is hoped that the results may also contribute to advancing the implementation of pharmaceutical care service in similar health systems. DESIGN: This is a case study using multiple sources of data. Qualitative and quantitative data were collected from institutional documents, by participant observation and interviews. Initial themes were identified by content analysis and analyzed under the context-mechanism-outcome configurations (CMO Configurations) in realistic evaluation. SETTING: Geriatrics and Gerontology Institute of São Paulo (known as IPGG). PARTICIPANTS: Eleven health professionals and three pharmaceutical care service users. RESULTS: Three CMO configurations were identified and accepted: "Scenario Construction mediated by educational processes", "Contribution to complex needs resolution", and "Organizational Visibility". The CMO (Context-Mechanism-Outcomes) configuration "Logistic activities discourage clinical pharmaceutical services implantation" was denied due to the influence of accepted CMOs. CONCLUSIONS: Educational processes which value transdisciplinary knowledge exchanges provide resources required to overcome important obstacles present during pharmaceutical care implementation. Thus, providing and seeking knowledge to build and offer context-consistent clinical health services as well as fulfilling organizational environment requirements can be the key to implement pharmaceutical care service.


Assuntos
Assistência Ambulatorial/organização & administração , Serviços de Saúde para Idosos/organização & administração , Assistência Farmacêutica/organização & administração , Idoso , Brasil , Pesquisa sobre Serviços de Saúde , Humanos , Estudos de Casos Organizacionais , Saúde Pública , Pesquisa Qualitativa
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA